FY2029 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure N.V. (NASDAQ:QURE) – HC Wainwright upped their FY2029 EPS estimates for uniQure in a report released on Monday, October 6th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn $20.48 per share for the year, up from their prior forecast of $20.36. HC Wainwright currently has a “Buy” rating and a $110.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share.

QURE has been the subject of a number of other research reports. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, August 2nd. The Goldman Sachs Group upped their target price on shares of uniQure from $13.00 to $56.00 and gave the stock a “neutral” rating in a research report on Thursday, September 25th. UBS Group set a $95.00 target price on shares of uniQure in a research report on Thursday, September 25th. Leerink Partners upped their target price on shares of uniQure from $48.00 to $68.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 24th. Finally, Mizuho upped their target price on shares of uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.75.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $57.92 on Tuesday. The firm has a fifty day moving average price of $23.23 and a 200-day moving average price of $16.96. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The stock has a market cap of $3.18 billion, a PE ratio of -14.78 and a beta of 0.56. uniQure has a 1 year low of $5.23 and a 1 year high of $60.70.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.20. The firm had revenue of $5.26 million during the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 226,316 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the transaction, the chief executive officer owned 651,454 shares in the company, valued at $27,009,282.84. This trade represents a 25.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christian Klemt sold 15,000 shares of the stock in a transaction on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer owned 217,730 shares of the company’s stock, valued at $11,975,150. This trade represents a 6.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 244,316 shares of company stock valued at $10,328,181 in the last quarter. 4.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its position in uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,538 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of uniQure in the 2nd quarter worth about $117,000. Mraz Amerine & Associates Inc. bought a new stake in shares of uniQure in the 1st quarter worth about $106,000. Teacher Retirement System of Texas bought a new stake in shares of uniQure in the 2nd quarter worth about $151,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of uniQure in the 1st quarter worth about $152,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.